US OptionsDetailed Quotes
SGMO250117C1500
- 0.05
- -0.87-94.57%
15min DelayClose Dec 31 16:00 ET
0.45High0.05Low
0.45Open0.92Pre Close1.21K Volume197 Open Interest1.50Strike Price11.48KTurnover233.97%IV51.96%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2980Delta0.6882Gamma13.60Leverage Ratio-0.0054Theta0.0001Rho4.05Eff Leverage0.0007Vega
Sangamo Therapeutics Stock Discussion
Sign in to post a comment
The trading year ended with markets declining
Shortly after close, the $S&P 500 Index (.SPX.US)$ dipped 0.43% to 5,881.63, the $Dow Jones Industrial Average (.DJI.US)$ edged down 0.07% to 42,544.22, and the $Nasdaq Composite Index (.IXIC.US)$ dropped 0.9% to 19,310.79.
For the year, the Nasdaq Composite led the way, rising 29%. The S&P 500 was up 23% (a second straight year of 20% gains) and the Dow added almost 13%.
MACR...
Shortly after close, the $S&P 500 Index (.SPX.US)$ dipped 0.43% to 5,881.63, the $Dow Jones Industrial Average (.DJI.US)$ edged down 0.07% to 42,544.22, and the $Nasdaq Composite Index (.IXIC.US)$ dropped 0.9% to 19,310.79.
For the year, the Nasdaq Composite led the way, rising 29%. The S&P 500 was up 23% (a second straight year of 20% gains) and the Dow added almost 13%.
MACR...
56
3
8
Barclay's keeps overweight and maintains 9 dollar target. Says they assigned limited value to the Hemo A program. Very Intresting
4
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. No buy pressure/momentum- No day t...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. No buy pressure/momentum- No day t...
70
23
9
$Sangamo Therapeutics (SGMO.US)$ buy buy buy
3
1
$Sangamo Therapeutics (SGMO.US)$ Yup yup! Looks as it could be a swing opportunity? I dont think the news warrants this type of drop? Ifn there was a bunch sitting on the sidelines looking for a lower in? Well they just got it! Hehehe
3
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Sangamo Therapeutics (SGMO.US)$ Sangamo Says Collaboration, License Agreement With Pfizer On Giroctocogene Fitelparvovec Will Terminate Effective April 21, 2025; Plans To Explore All Options To Commercialize The Asset, Including Seeking Potential New Partner
Benzinga· 4 mins ago
Sangamo believes that its recently announced partnerships with Genentech and Astellas, and advanced business development discussions for its Fabry gene therapy program, will allow it to chart a path forward for its n...
Benzinga· 4 mins ago
Sangamo believes that its recently announced partnerships with Genentech and Astellas, and advanced business development discussions for its Fabry gene therapy program, will allow it to chart a path forward for its n...
$Sangamo Therapeutics (SGMO.US)$
Should be interesting to see what we get in up front. It's been given Accelerated Approval by FDA so BLA will be filed next year sometime once we get final patient data. I'm guessing 100 to 200 million up front.
Should be interesting to see what we get in up front. It's been given Accelerated Approval by FDA so BLA will be filed next year sometime once we get final patient data. I'm guessing 100 to 200 million up front.
No comment yet
102450766 : M
103677010 : noted
101896186 : Looking for a reversal next week